<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547907</url>
  </required_header>
  <id_info>
    <org_study_id>HNCH-BC006</org_study_id>
    <nct_id>NCT04547907</nct_id>
  </id_info>
  <brief_title>Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer, A Multicenter, Randomized, Phase III Clinical Trial</brief_title>
  <official_title>Comparing the Efficacy of Nab-PHP(Albumin Bound Paclitaxel + Trastuzumab + Patuzumab) and TCbHP(Docetaxel + Carboplatin + Trastuzumab + Patuzumab) in Neoadjuvant Chemotherapy for HER2 Positive Operable Breast Cancer , A Multicenter, Randomized, Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, trastuzumab combined with patuzumab has become the standard neoadjuvant therapy&#xD;
      for high-risk HER2 positive breast cancer. TCbHP has been the standard choice of neoadjuvant&#xD;
      therapy for HER2 positive breast cancer patients with early high-risk or locally advanced&#xD;
      HER2 positive breast cancer. Whether nab-PHP can achieve the same effect as TCbHP is still&#xD;
      uncertain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Percentage of Participants With Pathological Complete Response (pCR) (ypT0/is/N0M0) after 6 cycles of neoadjuvant chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Baseline up to cycle 4 (assessed at Baseline, at the time of pre-surgery)up to approximately 12 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>Following surgery until Year 5</time_frame>
    <description>Disease-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Following surgery until Year 5</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Incidence and severity of adverse events classified by NCI CTCAE4.0</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">558</enrollment>
  <condition>Breast Cancer,Her2 Positive</condition>
  <arm_group>
    <arm_group_label>nab-PHP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albumin binding paclitaxel + trastuzumab+ patuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCbHP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel + carboplatin + trastuzumab + patuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin binding paclitaxel+ trastuzumab+ patuzumab</intervention_name>
    <description>Albumin binding paclitaxel 125 mg / m2 (1, 8, 15 days) + trastuzumab (8 mg / kg for the first loading dose and 6 mg / kg for the sequential maintenance dose) + patuzumab (840mg for the first loading dose and 420mg for the sequential maintenance dose) ，every 21 days for 6 cycles.</description>
    <arm_group_label>nab-PHP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel+ carboplatin+ trastuzumab + patuzumab</intervention_name>
    <description>Docetaxel 75 mg/m2 + carboplatin (AUC = 6) + trastuzumab(8 mg / kg for the first loading dose and 6 mg / kg for the sequential maintenance dose) + patuzumab (840mg for the first loading dose and 420mg for the sequential maintenance dose) ，every 21 days for 6 cycles.</description>
    <arm_group_label>TCbHP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years ≤ age ≤ 75 years, Performance Status- Eastern Cooperative Oncology Group&#xD;
             (ECOG) 0-1&#xD;
&#xD;
          2. Clinical T2-T4d, or T1c with axillary LN+&#xD;
&#xD;
          3. HER2 + invasive breast cancer confirmed by histopathology Note: HER2 expression&#xD;
             positive refers to the tumor cells with immunohistochemical staining intensity of 3 +&#xD;
             or confirmed positive by fluorescence in situ hybridization [fish] at least once&#xD;
             during the pathological detection/review of primary tumor in the Department of&#xD;
             pathology of participating research center hospital&#xD;
&#xD;
          4. Clinically measurable lesions: measurable lesions revealed by ultrasound, molybdenum&#xD;
             target or MR (optional) within 1 month before randomization&#xD;
&#xD;
          5. Organ and bone marrow function test within one month before chemotherapy showed no&#xD;
             chemotherapy contraindication&#xD;
&#xD;
               -  Absolute value of neutrophil count ≥ 2.0×10^9 / L&#xD;
&#xD;
               -  Hemoglobin ≥ 100g / L&#xD;
&#xD;
               -  Platelet count ≥ 100×10^9 / L&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 ULN (upper limit of normal value)&#xD;
&#xD;
               -  Creatinine &lt; 1.5 × ULN&#xD;
&#xD;
               -  AST/ALT &lt; 1.5×ULN&#xD;
&#xD;
          6. Echocardiography: left ventricular ejection fraction (LVEF ≥ 55%)&#xD;
&#xD;
          7. For women of childbearing age, serum pregnancy test was negative 14 days before&#xD;
             randomization&#xD;
&#xD;
          8. KPS score ≥ 80 points&#xD;
&#xD;
          9. Signed the informed consent form prior to patient entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic disease (Stage IV)&#xD;
&#xD;
          2. Chemotherapy, endocrine therapy, targeted therapy and reflexotherapy have been used&#xD;
             for this disease&#xD;
&#xD;
          3. The patient had a second primary malignant tumor, except for the well treated skin&#xD;
             cancer&#xD;
&#xD;
          4. Patients who had undergone major surgery unrelated to breast cancer within 4 weeks&#xD;
             before enrollment, or had not recovered completely from such operations&#xD;
&#xD;
          5. Serious heart disease or discomfort, including but not limited to the following&#xD;
             diseases:&#xD;
&#xD;
               -  History of heart failure or systolic dysfunction (LVEF &lt; 50%)&#xD;
&#xD;
               -  high risk uncontrolled arrhythmias such as atrial tachycardia, resting heart rate&#xD;
                  &gt; 100 BPM, significant ventricular arrhythmias (e.g., ventricular tachycardia) or&#xD;
                  higher-level atrioventricular block (i.e., mobitz II second degree&#xD;
                  atrioventricular block or third degree atrioventricular block)&#xD;
&#xD;
               -  angina pectoris requiring anti angina drugs&#xD;
&#xD;
               -  Heart valve disease with clinical significance&#xD;
&#xD;
               -  ECG showed transmural myocardial infarction&#xD;
&#xD;
               -  Poor control of hypertension (systolic blood pressure &gt; 180 mmHg and / or&#xD;
                  diastolic blood pressure &gt; 100 mmHg)&#xD;
&#xD;
          6. Due to serious and uncontrollable other medical diseases, the researchers believe that&#xD;
             there are chemotherapy contraindications&#xD;
&#xD;
          7. Those who have been known to have allergic history to the drug components of this&#xD;
             regimen; have a history of immune deficiency, including HIV positive test, or have&#xD;
             other acquired or congenital immunodeficiency diseases, or have a history of organ&#xD;
             transplantation;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenzhen Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhenzhen Liu</last_name>
    <phone>13603862755</phone>
    <email>liuzhenzhen73@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiujun Zhu</last_name>
    <phone>13676962766</phone>
    <email>bigapple0601@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan cancer hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenzhen Liu</last_name>
      <phone>17729798130</phone>
      <email>liuzhenzhen73@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Liuzhenzhen</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

